A Phase 1, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB067 Administered to Adult Subjects With Amyotrophic Lateral Sclerosis

Trial Profile

A Phase 1, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB067 Administered to Adult Subjects With Amyotrophic Lateral Sclerosis

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Sep 2017

At a glance

  • Drugs ISIS SOD1Rx (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Biogen
  • Most Recent Events

    • 27 Mar 2017 Planned End Date changed from 1 Apr 2018 to 1 Jul 2018.
    • 27 Mar 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Jul 2018.
    • 11 Dec 2015 Status changed from not yet recruiting to recruiting, according to an Isis Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top